Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects or their legally authorized representative must provide a signed and dated informed consent form to participate in the study.~2. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study.~3. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements.~4. Subjects must have successfully completed all Study MT-1186-A02 visits and have been compliant with study drug.~Exclusion Criteria:~1. Subjects of childbearing potential unwilling to use an acceptable method of contraception from the Day 1/screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period.~2. Subjects who are female, of childbearing potential, and pregnant (a positive pregnancy test) or lactating at the Day 1/screening visit.~3. Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) at Week 48 of Study MT-1186-A02.~4. Subjects who are not eligible to continue in the study, as judged by the Investigator in conjunction with the MTDA medical monitor.~5. Subjects who are unable to take their medications orally or through a PEG/RIG tube.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MT-1186 - Group 1 (Type: EXPERIMENTAL): Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.
- MT-1186 - Group 2 (Type: EXPERIMENTAL): Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.

Based on this trial design, predict the completion outcome and termination type (if applicable).